In its latest quarterly and annual filings, Immunovant, Inc. confirmed a strategic shift concentrating resources on IMVT-1402, its lead product candidate targeting FcRn to reduce pathogenic IgG in autoimmune diseases. This pivot follows the discontinuation of batoclimab development after failed Phase 3 trials in thyroid eye disease. The company maintains a solid financial foundation, with over $900 million in cash as of March 31, 2026, sufficient to fund anticipated operations through regulatory milestones. Immunovant’s multi-indication clinical development program aims for potential registrational studies across six autoimmune conditions, leveraging proprietary technology licensed from HanAll Biopharma. Key risks include clinical trial execution, dependency on licensed intellectual property, and the need for additional capital beyond the current runway.